179 results about "In vivo absorption" patented technology

Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.

The invention belongs to the field of pharmacy and particularly relates to a medicinal preparation of palbociclib and a preparing method thereof. The medicinal preparation comprises palbociclib, an acidic adjuvant and an optional hydrophily high-molecular material. Compared with a conventional preparation, the medicinal preparation has more excellent solubility and in-vitro dissolution property, and can be used for enhancing in-vivo adsorption and bioavailability of palbociclib.

Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.

The preparation for intranasal administration comprising D-alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide (pralmorelin) and/or an acid addition salt thereof as an active ingredient and water permits a marked increase in the in vivo absorption of pralmorelin and hence provides adequate efficacy even if it is administered in a small dose at a time. The preparation also allows pralmorelin to be dissolved in an increased amount, so it can be formulated pharmaceutically with great ease. It also high stability over time.

The invention relates to porous magnesium matrix composite tissue engineering scaffold biomaterial which can degrade in the bio-body. The components and the volume percent contents are 70 percent to 20 percent of high purity magnesium and magnesium alloy powder, 10 percent to 20 percent of HA powder and 20 percent to 70 percent of pore forming agent, the high purity magnesium and the magnesium alloy powder are HA alloys, high purity magnesium alloys, high purity Mg-Zn alloys, high purity Mg-Zn-Ca alloys, high purity Mg-Zn-Ca-Fe alloys, high purity Mg-Mn alloys and high purity Mg-Zn-Mn alloys, and the purity rate of the alloy is higher than or equal to 99.99 percent. The bone tissue engineering scaffold biomaterial prepared by the invention which adopts the powder metallurgy technology utilizes the chemical reaction of the magnesium in aqueous medium to be converted into magnesium ions, and the magnesium ions adjust the balance through the in vivo absorption and the kidney metabolism, thereby leading the scaffold to be gradually degraded and absorbed in vivo.

The invention discloses a berberine hydrochloride medicinal composition and a preparation method thereof, which are used for increasing the dissolution rate of berberine hydrochloride in water and enhance the in-vivo absorption of berberine hydrochloride. According to the specific technical scheme, berberine hydrochloride serves as a medicinal active ingredient of the composition; and a filling agent, a disintegrating agent, a flavoring agent and a lubricating agent in the weight ratio (1-50):(25-60):(3-15):(1.5-3):(0.4-1.2) serve as auxiliary materials. The method for preparing the berberine hydrochloride medicinal composition comprises the following steps of: (1) dissolving; (2) drying; (3) screening; and (4) tableting. The berberine hydrochloride medicinal composition prepared with the method has high disintegrating and dissolving speeds and a good medicament effect, and the problems of low solubility and unstable absorption of berberine hydrochloride are solved. The berberine hydrochloride medicinal composition is effective to enteral infection caused by dysentery bacillus and colon bacillus, and is used for treating enteral infection and diarrhea.

The invention discloses a preparation method and application of a bioactive nanometer organic zinc and selenium animal and plant nutrient solution. The method comprises the following steps: weighing raw materials in the following mass percent, and adding the following raw materials in every 5000kg of water: 8 to 12kg of maltose, 15 to 25kg of sodium cyclamate, 15 to 25g of gelatin, 15 to 25g of chitosan, 25 to 35g of zinc oxide, 450 to 550g of lysine, 35 to 45g of sodium tetraborate, 95 to 105g of glycine betaine, 95 to 105g of nonprotein nitrogen, 95 to 105g of beta-glucolase, 450 to 550g of saccharomycetes, 450 to 550g of selenium philic bacillus laterosporus, and 25 to 35g of selenium dioxide; weighing and uniformly mixing and stirring the raw materials, and performing fermentation on the raw materials for 15 to 20 days at 25 to 35 DEG C, so as to obtain the nutrient solution. The nutrient solution can not only ensure that plants accelerate absorb and enrich organic zinc and selenium, but also can promote the plants to perform in vivo absorption on various nutrients beneficial to growth and improvement of the mouthfeel, enables the egg dead rate to be greater than 95 percent, is odorless, environmental-friendly, convenient to apply, uniform, does not destroy roots and seedlings, improves the plant quality and yield, and can further improve the antiviral and anti-infective ability of animals.

The invention specifically relates to a celecoxib solid dispersion and a preparation method and application thereof. The celecoxib solid dispersion is prepared from celecoxib and poloxamer 188 at a mass ratio of 1:(1-20) by a melting process and a solvent process. The dispersion provided by the invention has good dispersity and high stability; the solubility and dissolution rate of the medicine are increased; the solubility of the medicine in water is 5-200 times higher than that of the raw medicines; with good dissolution rate in water, the in-vivo absorption of the medicine can be enhanced so as to improve the bioavailability. The solid dispersion also can be made into multiple clinically acceptable dosage forms which are used as new dosage forms of celecoxib.

The invention relates to a pharmaceutical composition which comprises dronedarone or pharmaceutically acceptable salt thereof used as a preparation active ingredient, a phosphatide, an acidity regulator and one or more crystallization inhibitors. The composition is suitable for any oral drug forms, such as tablets, capsules or granules. The composition has the advantages that: the drug dissolution can be effectively increased, thereby increasing the in-vivo absorption rate and degree of the active ingredients; and more importantly, the areas below the in-vivo blood concentration-time curves of the Beagle dog under drug feeding/fasting conditions have no difference almost.

The invention relates to a technology of improving the in-vitro dissolution of an indissolvable medicament, discloses a self-microemulsion, and especially discloses an ATPR (4-Amino-2-Trifluoromethyl Phenyl Retinoate) self-microemulsion and a preparation method thereof. The ATPR self-microemulsion is characterized by being prepared from the following components by weight percent: 0.1-20% of ATPR, 1-30% of oil phase, 40-85% of surfactant and 1-40% of cosurfactant. The self-microemulsion and the preparation method provided by the invention have the following beneficial effects: the solubility of the medicament is improved by the ATPR self-microemulsion drug release system, the medicament is dissolved in oil drops and thus protected and the stability of the medicament in vivo is improved, the surfactant is capable of changing the liquidity of the cell membrane and improving the membrane permeability of the medicament, so that the in-vivo absorption of the medicament is increased and the relative bioavailability of the medicament is improved. Besides, the solid self-microemulsion is capable of improving the phenomena of softening and oil leakage of the traditional soft capsules and enhancing the stability of the preparation.

The invention provides a radioisotope labeled meso-porous bioglass porous scaffold. A meso-porous bioglass porous scaffold is labeled with radioisotope, and the radioisotope can be one or more of <31>Si, <32>P and <45>Ca. The radioisotope labeled meso-porous bioglass porous scaffold can effectively label the meso-porous bioglass porous scaffold, can quantitatively and intuitively detect the in vivo degradation situation of the meso-porous bioglass porous scaffold, and can be used to research the in vivo absorption and the organism distribution of the bioglass scaffold.

The invention provides an ezetimibe tablet and a preparation method thereof. The ezetimibe tablet is prepared from the following components in parts by weight: 10 parts of ezetimibe, 10 parts of a disintegrating agent, 2 parts of a solubilizing agent, 55 to 70 parts of a filling agent, 5 to 15 parts of microcrystalline cellulose, 5 parts of an adhesive and 0.5 parts of a lubricant. According to the ezetimibe tablet disclosed by the invention, the fluctuation of the dissolution of the ezetimibe tablet can be effectively reduced, the dissolution difference is reduced, the safety of the ezetimibe tablet in a medicine using process is improved, and the fluctuation of in-vivo absorption of the ezetimibe tablet is reduced; meanwhile, according to the preparation method of the ezetimibe tablet, a production process is simplified, and the method can adapt to large-scale industrial production.

The invention belongs to the field of pharmaceutical preparations and discloses a nimodipine lipid nanoparticle and a preparation technology thereof. The lipid nanoparticle is prepared by an emulsification-evaporation technique combined with a high pressure homogenization method, and a drug is encapsulated in a lipid carrier to form a stable and homogeneous colloidal solution. The prepared lipid nanoparticle is small in nanoparticle size, high in dispersity, good in stability, and capable of releasing the drug slowly and permanently and improving the in vivo absorption of the drug. The preparation technology is simple, low in cost, free from residual organic solvent, low in biological toxicity, and easy to realize industrial production.

The present invention provides a pharmaceutical composition and a food composition for preventing or treating lipid-related metabolic disease, which contain, as active ingredients, probiotics and a vitamin B complex. When the composition comprising the probiotics and the vitamin B complex is used, it may further promote in vivo absorption of the vitamin B complex, and may induce a synergistic effect on a reduction in blood lipid levels, thereby exhibiting an effect on the alleviation, prevention or treatment of obesity and lipid-related metabolic disease.

The invention discloses a multi-variant and multi-phase salvia miltiorrhiza solid self-microemulsion, application thereof in preparation of a drug and a preparation method thereof. A solid self-microemulsion composition is prepared from the following components by weight: 0.1-10g of salvia miltiorrhiza multi-component extract, 10-30g of emulsifier, 5-20g of co-emulsifier, 10-30g of oil phase and 20-50g of solid adsorbent. Two components (total tanshinones and salvianolic acids) in the salvia miltiorrhiza are simultaneously loaded to one preparation; in vivo absorption of a plurality of ingredients in the salvia miltiorrhiza is improved. By adopting the preparation method, the stability of the self-microemulsion preparation can be increased; the dosage of a surfactant is greatly reduced; meanwhile, the bioavailability of a multi-component extract of the salvia miltiorrhiza is improved.